Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Details)

v3.19.3
Commitments and Contingencies - Additional Information (Details)
9 Months Ended
Apr. 10, 2015
Sep. 30, 2019
USD ($)
Sep. 30, 2019
EUR (€)
Supply Commitment [Line Items]      
Lessee, operating lease, option to extend   Periods covered by an option to extend the lease were included in the non-cancellable lease term when exercise of the option was determined to be reasonably certain. Periods covered by an option to extend the lease were included in the non-cancellable lease term when exercise of the option was determined to be reasonably certain.
Lessee, operating lease, existence of option to extend   true true
Operating lease, weighted average remaining term   3 years  
Operating lease, weighted average discount rate percent   16.00%  
Purchase Commitment      
Supply Commitment [Line Items]      
Purchase commitment non cancelable and cancelable   $ 4,863,000  
Minimum      
Supply Commitment [Line Items]      
Operating leases with remaining lease term   1 year  
Maximum      
Supply Commitment [Line Items]      
Operating leases with remaining lease term   3 years  
Maximum | Executive Officer      
Supply Commitment [Line Items]      
Aggregate annual base salaries of employment agreements   $ 624,000  
Recro | Gainesville Facility      
Supply Commitment [Line Items]      
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones   $ 140,000,000  
Maximum future net product sales milestone percentage 30.00% 30.00% 30.00%
Recro | Gainesville Facility | Regulatory Approval and Net Sales Milestones      
Supply Commitment [Line Items]      
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones   $ 50,000,000  
Collaborative arrangements, milestone payments period   7 years 7 years
Recro | Alkermes Plc      
Supply Commitment [Line Items]      
Collaborative Arrangements Milestone Payments upon Achievement of Regulatory and Sales Milestones   $ 10,000,000  
Recro | Minimum | Gainesville Facility      
Supply Commitment [Line Items]      
Future net product sales milestone percentage 10.00% 10.00% 10.00%
Recro | Maximum | Gainesville Facility      
Supply Commitment [Line Items]      
Future net product sales milestone percentage 12.00% 12.00% 12.00%
Recro | Dexmedetomidine License Agreement      
Supply Commitment [Line Items]      
Contingent milestone payments, maximum   $ 22,380,000 € 20,500,000
Amount of royalty payments due or payable   $ 0  
Recro | Dexmedetomidine License Agreement | Minimum      
Supply Commitment [Line Items]      
Percentage of royalty payments   10.00% 10.00%
Recro | Dexmedetomidine License Agreement | Maximum      
Supply Commitment [Line Items]      
Percentage of royalty payments   20.00% 20.00%
Recro | Fadolmidine License Agreement      
Supply Commitment [Line Items]      
Amount of royalty payments due or payable   $ 0  
Additional contingent milestones payment   $ 13,320,000 € 12,200,000
Recro | Fadolmidine License Agreement | Minimum      
Supply Commitment [Line Items]      
Percentage of royalty payments   10.00% 10.00%
Recro | Fadolmidine License Agreement | Maximum      
Supply Commitment [Line Items]      
Percentage of royalty payments   15.00% 15.00%